close

News

LATEST POSTS from News

Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform

Envisagenics Raises Series A Financing to Scale its AI-powered RNA Splicing Drug Discovery Platform Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug discovery platform and biopharmaceutical partnerships. Red Cell Partners led the financing,…..

Endeavor BioMedicines gains rights to lead ULK1/2 inhibitor molecule

Endeavor BioMedicines gains rights to lead ULK1/2 inhibitor molecule Endeavor BioMedicines, a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis, has concluded an exclusive licensing agreement with the Salk Institute, along with Sanford Burnham Prebys. Under the license agreement, the California-based company…..

TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies

TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series…..

Clean Biologics is acquiring Biodextris

Clean Biologics is acquiring Biodextris  Clean Biologics, a French group providing services to the biopharmaceutical industry,  is acquiring Biodextris, a Contract Development and Manufacturing Organization (CDMO) based in Laval (Montreal), Canada. Biodextris provides analytical and process development, early-phase clinical manufacturing and quality control testing services for clients in the vaccine…..